Annexon (ANNX) Operating Expenses (2019 - 2026)
Annexon (ANNX) posted quarterly Operating Expenses of $46.1 million for Q1 2026, down 19.78% year-over-year from $57.4 million in Q1 2025, and down 8.37% quarter-over-quarter from $50.3 million in Q4 2025.
Annexon (ANNX) Operating Expenses (2019 - 2026) Analysis & Trends
Annexon's Operating Expenses history runs 8 years deep, the most recent figure standing at $46.1 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 19.78% year-over-year to $46.1 million; the TTM figure through Mar 2026 stood at $205.1 million (up 12.11% YoY), while the FY2025 annual figure was $216.4 million, up 40.46% from the prior year.
- Operating Expenses for Q1 2026 stood at $46.1 million, down from $50.3 million in the prior quarter.
- The five-year high for Operating Expenses was $57.4 million in Q1 2025, with the low at $28.6 million in Q1 2024.
- The 5-year median for Operating Expenses is $37.7 million (2023), against an average of $41.5 million.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses sank 30.72% in 2024, then surged 100.91% in 2025.
- Annexon's Operating Expenses stood at $36.7 million in 2022, then slipped by 18.22% to $30.0 million in 2023, then soared by 74.88% to $52.5 million in 2024, then slipped by 4.23% to $50.3 million in 2025, then declined by 8.37% to $46.1 million in 2026.
- Business Quant data shows ANNX's Operating Expenses at $46.1 million in Q1 2026, $50.3 million in Q4 2025, and $57.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | 57.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 57.23 Mn |
| Mar 31, 2026 | 46.05 Mn |
| Dec 31, 2025 | 50.26 Mn |
| Sep 30, 2025 | 57.02 Mn |
| Jun 30, 2025 | 51.73 Mn |
| Mar 31, 2025 | 57.41 Mn |
| Dec 31, 2024 | 52.48 Mn |
| Sep 30, 2024 | 39.44 Mn |
| Jun 30, 2024 | 33.58 Mn |
| Mar 31, 2024 | 28.57 Mn |
| Dec 31, 2023 | 30.01 Mn |
| Sep 30, 2023 | 34.78 Mn |
| Jun 30, 2023 | 37.69 Mn |
| Mar 31, 2023 | 41.24 Mn |
| Dec 31, 2022 | 36.70 Mn |
| Sep 30, 2022 | 36.07 Mn |
| Jun 30, 2022 | 37.41 Mn |
| Mar 31, 2022 | 35.43 Mn |
| Dec 31, 2021 | 37.46 Mn |
| Sep 30, 2021 | 35.68 Mn |